Mesenchymal Stromal Cell Exosomes for Drug Delivery of Prostate Cancer Treatments: a Review

Overview

Journal Stem Cell Res Ther

Publisher Biomed Central

Date 2025 Jan 24

PMID 39849570

Authors

Chengran Wang

Yanshuo Feng

Xinao Rong

Jingguo Yan

Baisong Lv

Hongyu Jiang

Lian Duan

Jinlan Jiang

Affiliations

Soon will be listed here.

Abstract

Interest in prostate cancer as a research topic has gradually increased. As a result, a series of innovative treatment strategies have emerged with an in-depth understanding of the disease. Owing to their unique biological characteristics, mesenchymal stromal cell exosomes (MSC-Exos) have garnered significant attention for their potential to deliver targeted drugs and enable precise prostate cancer treatment. Herein, prostate cancer treatment with MSC-Exos drug-delivery systems is reviewed. This review provides a comprehensive introduction to the advantages of these systems, current research trends and progress, as well as an analysis of current challenges and future research directions. Moreover, this review lays a solid foundation for the continued development and application of MSC-Exos.

References

Kooijmans S, Aleza C, Roffler S, van Solinge W, Vader P, Schiffelers R . Display of GPI-anchored anti-EGFR nanobodies on extracellular vesicles promotes tumour cell targeting. J Extracell Vesicles. 2016; 5:31053. PMC: 4793259. DOI: 10.3402/jev.v5.31053. View

Guo Z, Wang G, Yun Z, Li Y, Huang B, Jin Q . Global research trends in tumor stem cell-derived exosomes and tumor microenvironment: visualization biology analysis. J Cancer Res Clin Oncol. 2023; 149(19):17581-17595. PMC: 10657319. DOI: 10.1007/s00432-023-05450-2. View

Mendt M, Kamerkar S, Sugimoto H, McAndrews K, Wu C, Gagea M . Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018; 3(8). PMC: 5931131. DOI: 10.1172/jci.insight.99263. View

Ramesh D, Bakkannavar S, Bhat V, Sharan K . Extracellular vesicles as novel drug delivery systems to target cancer and other diseases: Recent advancements and future perspectives. F1000Res. 2023; 12:329. PMC: 10589634. DOI: 10.12688/f1000research.132186.1. View

Williams C, Harry R, McLeod J . Apoptotic cells induce dendritic cell-mediated suppression via interferon-gamma-induced IDO. Immunology. 2007; 124(1):89-101. PMC: 2434374. DOI: 10.1111/j.1365-2567.2007.02743.x. View

Menges D, Yebyo H, Sivec-Muniz S, Haile S, Barbier M, Tomonaga Y . Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. Eur Urol Oncol. 2022; 5(6):605-616. DOI: 10.1016/j.euo.2022.04.007. View

Sun Y, Liu G, Zhang K, Cao Q, Liu T, Li J . Mesenchymal stem cells-derived exosomes for drug delivery. Stem Cell Res Ther. 2021; 12(1):561. PMC: 8557580. DOI: 10.1186/s13287-021-02629-7. View

Koh H, Kim H, Kang S, Yoo T . Exosome-Based Drug Delivery: Translation from Bench to Clinic. Pharmaceutics. 2023; 15(8). PMC: 10459753. DOI: 10.3390/pharmaceutics15082042. View

Abdelsalam M, Ahmed M, Osaid Z, Hamoudi R, Harati R . Insights into Exosome Transport through the Blood-Brain Barrier and the Potential Therapeutical Applications in Brain Diseases. Pharmaceuticals (Basel). 2023; 16(4). PMC: 10144189. DOI: 10.3390/ph16040571. View

10.

Barile L, Vassalli G . Exosomes: Therapy delivery tools and biomarkers of diseases. Pharmacol Ther. 2017; 174:63-78. DOI: 10.1016/j.pharmthera.2017.02.020. View

11.

Lainscek D, Kadunc L, Keber M, Bratkovic I, Romih R, Jerala R . Delivery of an Artificial Transcription Regulator dCas9-VPR by Extracellular Vesicles for Therapeutic Gene Activation. ACS Synth Biol. 2018; 7(12):2715-2725. DOI: 10.1021/acssynbio.8b00192. View

12.

Cheng B, Li L, Luo T, Wang Q, Luo Y, Bai S . Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway. J Exp Clin Cancer Res. 2024; 43(1):67. PMC: 10905933. DOI: 10.1186/s13046-024-02962-8. View

13.

Siraj Y, Galderisi U, Alessio N . Senescence induces fundamental changes in the secretome of mesenchymal stromal cells (MSCs): implications for the therapeutic use of MSCs and their derivates. Front Bioeng Biotechnol. 2023; 11:1148761. PMC: 10203235. DOI: 10.3389/fbioe.2023.1148761. View

14.

Zhou Y, Zhou W, Chen X, Wang Q, Li C, Chen Q . Bone marrow mesenchymal stem cells-derived exosomes for penetrating and targeted chemotherapy of pancreatic cancer. Acta Pharm Sin B. 2020; 10(8):1563-1575. PMC: 7488356. DOI: 10.1016/j.apsb.2019.11.013. View

15.

Lin Z, Wu Y, Xu Y, Li G, Li Z, Liu T . Mesenchymal stem cell-derived exosomes in cancer therapy resistance: recent advances and therapeutic potential. Mol Cancer. 2022; 21(1):179. PMC: 9468526. DOI: 10.1186/s12943-022-01650-5. View

16.

Kulus M, Sibiak R, Stefanska K, Zdun M, Wieczorkiewicz M, Piotrowska-Kempisty H . Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues-Origins, Characteristics, Signaling Pathways, and Clinical Trials. Cells. 2021; 10(12). PMC: 8699543. DOI: 10.3390/cells10123278. View

17.

Jackson C, Choi J, Lim M . Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019; 20(9):1100-1109. DOI: 10.1038/s41590-019-0433-y. View

18.

Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Hervieu A, Hennequin A . Monitoring HSP70 exosomes in cancer patients' follow up: a clinical prospective pilot study. J Extracell Vesicles. 2020; 9(1):1766192. PMC: 7301715. DOI: 10.1080/20013078.2020.1766192. View

19.

Hao R, Yu Z, Du J, Hu S, Yuan C, Guo H . A High-Throughput Nanofluidic Device for Exosome Nanoporation to Develop Cargo Delivery Vehicles. Small. 2021; 17(35):e2102150. DOI: 10.1002/smll.202102150. View

20.

Yanagisawa T, Rajwa P, Thibault C, Gandaglia G, Mori K, Kawada T . Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2022; 82(6):584-598. DOI: 10.1016/j.eururo.2022.08.002. View